CN110719911B - 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 - Google Patents
二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 Download PDFInfo
- Publication number
- CN110719911B CN110719911B CN201880039548.3A CN201880039548A CN110719911B CN 110719911 B CN110719911 B CN 110719911B CN 201880039548 A CN201880039548 A CN 201880039548A CN 110719911 B CN110719911 B CN 110719911B
- Authority
- CN
- China
- Prior art keywords
- formula
- group
- methyl
- fluorine
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211200547.7A CN115554300B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211199746.0A CN115554299A (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211200627.2A CN115583959B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17176046.5 | 2017-06-14 | ||
| EP17176046 | 2017-06-14 | ||
| EP17193252.8 | 2017-09-26 | ||
| EP17193252 | 2017-09-26 | ||
| PCT/EP2018/064977 WO2018228907A1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211200627.2A Division CN115583959B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211199746.0A Division CN115554299A (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211200547.7A Division CN115554300B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110719911A CN110719911A (zh) | 2020-01-21 |
| CN110719911B true CN110719911B (zh) | 2022-10-21 |
Family
ID=62492660
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211199746.0A Pending CN115554299A (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN201880039548.3A Active CN110719911B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211200627.2A Active CN115583959B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211200547.7A Active CN115554300B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211199746.0A Pending CN115554299A (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211200627.2A Active CN115583959B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
| CN202211200547.7A Active CN115554300B (zh) | 2017-06-14 | 2018-06-07 | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 |
Country Status (36)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20180056A7 (es) | 2015-12-10 | 2018-10-04 | Bayer Pharma AG | Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| TW202108139A (zh) * | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| TWI867088B (zh) | 2019-11-06 | 2024-12-21 | 德商拜耳廠股份有限公司 | 經取代之雜環甲醯胺及其用途 |
| MX2023000369A (es) * | 2020-07-06 | 2023-02-13 | Bayer Ag | Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño. |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
| US20250057845A1 (en) | 2021-12-22 | 2025-02-20 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea |
| KR20240127384A (ko) | 2021-12-22 | 2024-08-22 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물 |
| IL313652A (en) | 2021-12-22 | 2024-08-01 | Bayer Ag | Combination of a TASK1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |
| AU2023205312A1 (en) | 2022-01-07 | 2024-07-25 | Ocular Therapeutix, Inc. | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
| WO2023131640A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
| TW202529751A (zh) | 2023-09-28 | 2025-08-01 | 德商拜耳廠股份有限公司 | 經取代之雜環醯胺及其用途 |
| CN117959293B (zh) * | 2024-01-18 | 2025-05-13 | 香港大学深圳医院 | 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) * | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) * | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016085783A1 (en) * | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
| GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| AU2007245891B2 (en) | 2006-04-27 | 2012-10-18 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the TASK-1 and TASK-3 ion channel |
| AU2007272854B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| EP2300470A2 (en) | 2008-05-19 | 2011-03-30 | Sepracor Inc. | Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| NZ602311A (en) | 2010-03-18 | 2014-08-29 | Pasteur Institut Korea | Anti-infective compounds |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2708539A1 (de) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EP2671582B1 (en) | 2011-02-01 | 2016-07-13 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
| CA2831356A1 (en) | 2011-03-31 | 2012-10-04 | Emblem Technology Transfer Gmbh | Imidazo [1,2-a]pyridine_compounds for use in therapy |
| WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| BR112014005583A2 (pt) | 2011-09-12 | 2017-03-21 | Sanofi Sa | 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm |
| ES2559450T3 (es) | 2011-09-16 | 2016-02-12 | Sanofi | 4,5,6,7-Tetrahidro-1H-pirazolo[4,3-c]piridinas sustituidas, su uso como medicamento, y preparaciones farmacéuticas que las comprenden |
| WO2013113860A1 (en) | 2012-02-03 | 2013-08-08 | Sanofi | Fused pyrroledicarboxamides and their use as pharmaceuticals |
| EP3590939A1 (en) | 2014-03-26 | 2020-01-08 | F. Hoffmann-La Roche AG | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| WO2016085784A1 (en) | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
| TWI585785B (zh) * | 2014-11-26 | 2017-06-01 | Murata Manufacturing Co | Electronic parts manufacturing methods, electronic components and electronic devices |
| JP2018012645A (ja) | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
| JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ［２．２．２］オクタン誘導体 |
| MX2018002217A (es) | 2015-09-24 | 2018-03-23 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). |
| CU20180056A7 (es) | 2015-12-10 | 2018-10-04 | Bayer Pharma AG | Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios |
| WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| EP3886806A1 (de) | 2018-11-27 | 2021-10-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von pharmazeutischen darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| TW202108139A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
-
2017
- 2017-06-16 JO JOP/2019/0284A patent/JOP20190284A1/ar unknown
-
2018
- 2018-06-07 RS RS20240581A patent/RS65543B1/sr unknown
- 2018-06-07 PL PL18728646.3T patent/PL3638675T3/pl unknown
- 2018-06-07 MA MA49368A patent/MA49368B1/fr unknown
- 2018-06-07 US US16/622,233 patent/US11098063B2/en active Active
- 2018-06-07 HR HRP20240678TT patent/HRP20240678T1/hr unknown
- 2018-06-07 NZ NZ758821A patent/NZ758821A/en unknown
- 2018-06-07 CU CU2019000101A patent/CU24603B1/es unknown
- 2018-06-07 BR BR112019026450-7A patent/BR112019026450A2/pt not_active Application Discontinuation
- 2018-06-07 SG SG11201911508XA patent/SG11201911508XA/en unknown
- 2018-06-07 CA CA3066942A patent/CA3066942A1/en active Pending
- 2018-06-07 CN CN202211199746.0A patent/CN115554299A/zh active Pending
- 2018-06-07 EA EA202090043A patent/EA202090043A1/ru unknown
- 2018-06-07 JP JP2019569416A patent/JP6896113B2/ja active Active
- 2018-06-07 WO PCT/EP2018/064977 patent/WO2018228907A1/de not_active Ceased
- 2018-06-07 EP EP18728646.3A patent/EP3638675B1/de active Active
- 2018-06-07 KR KR1020207000676A patent/KR102364134B1/ko active Active
- 2018-06-07 CR CR20190563A patent/CR20190563A/es unknown
- 2018-06-07 PE PE2019002541A patent/PE20200016A1/es unknown
- 2018-06-07 CN CN201880039548.3A patent/CN110719911B/zh active Active
- 2018-06-07 GE GEAP201815256A patent/GEP20227366B/en unknown
- 2018-06-07 MX MX2019014983A patent/MX2019014983A/es unknown
- 2018-06-07 ES ES18728646T patent/ES2985167T3/es active Active
- 2018-06-07 AU AU2018283331A patent/AU2018283331B2/en not_active Ceased
- 2018-06-07 UA UAA202000222A patent/UA125186C2/uk unknown
- 2018-06-07 MY MYPI2019007414A patent/MY204293A/en unknown
- 2018-06-07 CN CN202211200627.2A patent/CN115583959B/zh active Active
- 2018-06-07 HU HUE18728646A patent/HUE066512T2/hu unknown
- 2018-06-07 CN CN202211200547.7A patent/CN115554300B/zh active Active
- 2018-06-12 TW TW107120117A patent/TWI801388B/zh active
- 2018-06-13 AR ARP180101619A patent/AR112099A1/es not_active Application Discontinuation
- 2018-06-14 UY UY0001037773A patent/UY37773A/es not_active Application Discontinuation
-
2019
- 2019-12-02 IL IL271117A patent/IL271117B/en unknown
- 2019-12-11 MX MX2022012716A patent/MX2022012716A/es unknown
- 2019-12-12 CL CL2019003650A patent/CL2019003650A1/es unknown
- 2019-12-12 EC ECSENADI201988492A patent/ECSP19088492A/es unknown
- 2019-12-12 CO CONC2019/0014047A patent/CO2019014047A2/es unknown
- 2019-12-12 NI NI201900126A patent/NI201900126A/es unknown
- 2019-12-13 PH PH12019502828A patent/PH12019502828A1/en unknown
- 2019-12-13 DO DO2019000308A patent/DOP2019000308A/es unknown
-
2021
- 2021-06-04 JP JP2021094338A patent/JP2021127346A/ja active Pending
- 2021-07-16 US US17/305,927 patent/US12180227B2/en active Active
-
2024
- 2024-11-21 US US18/955,853 patent/US20250154175A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) * | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) * | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016085783A1 (en) * | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110719911B (zh) | 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途 | |
| CN109476665B (zh) | 取代的二氮杂杂双环化合物及其用途 | |
| US10414765B2 (en) | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | |
| US11208422B2 (en) | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | |
| CN108290887A (zh) | 用于治疗睡眠相关的呼吸病症的作为task-1和task-2通道阻断剂的2-苯基-3-(哌嗪子基甲基)咪唑并[1,2-a]吡啶衍生物 | |
| HK40085267A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40085266A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40085269A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40015098B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40015098A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40085266B (zh) | 二氮杂双环取代的咪唑并嘧啶及其用於治疗呼吸障碍的用途 | |
| HK1262849A1 (en) | Substituted diazahetero-bicyclic compounds and their use | |
| HK1262849B (en) | Substituted diazahetero-bicyclic compounds and their use | |
| EA040559B1 (ru) | Диазабициклические замещенные имидазопиримидины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015098 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |